Ana Pereira - Neurology | Mount Sinai

Biography

Specialties

Neurology

Research Topics

Alzheimer's Disease, Cognitive Neurology, Cognitive Neuroscience

Research

Glutamatergic Neuronal Susceptibility

Dr. Pereira and her lab members have been studying glutamatergic neuronal susceptibility with modern quantitative cell biology methods in conjunction with molecular tools and functional assays. More details at Pereira Lab website https://labs.icahn.mssm.edu/pereiralab/

Risk Factors for Alzheimer's Disease

Pereira Lab has also been investigating risk factors for Alzheimer’s disease, such as intermittent hypoxia that occurs in sleep-disordered breathing and its mechanisms. These studies aim to develop novel preventive measures and therapeutic targets for age-related cognitive decline and Alzheimer’s disease. More details at Pereira Lab website https://labs.icahn.mssm.edu/pereiralab/

Translational and Clinical Studies

In parallel, as a physician-scientist, Dr. Pereira has been conducting translational and clinical studies using state-of-the-art neuroimaging and neuropsychological measures, including a clinical trial for a potential novel therapeutic intervention for patients with Alzheimer’s disease. More details at Pereira Lab website https://labs.icahn.mssm.edu/pereiralab/

Education

MD, Universidade Federal De Sao Paulo

MS, Translational and Clinical Investigation, Rockefeller University

Internship, Internal Medicine, Albert Einstein College of Medicine-Yeshiva University

Residency, Neurology, Harvard Medical School

Fellowship, Neurology, Columbia University Irving Medical Center

Certifications

American Board of Psychiatry and Neurology

Honors & Awards

2022

Alzheimer’s Association Grant Award

2021

Project Award

The Sanford Grossman Interdisciplinary Program in Neural Circuitry and Immune Function at ISMMS

2021

Medical Research Award

Robert J. and Claire Pasarow Foundation

2020

R01 Award

National Institutes of Health

2019

R01 Award

National Institutes of Health

2018

Alzheimer’s Association Research Grant Award

2017

Robertson Therapeutic Development Award

2016

Dana Foundation Award Recipient

2016

BrightFocus Award Recipient

2016

Bernard L. Schwartz Award for Physician Scientists

2016

NIH Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76)

2015

Young Investigator Award by the Alzheimer’s Drug Discovery Foundation

2015

Rockefeller University Pilot Project Award Recipient

2013

Alzheimer’s Drug Discovery Foundation Awarded Grant

2013

Appointed Chief Clinical Scholar at the Rockefeller University

2013

CTSA Pilot Project Award Recipient

2012

Diplomate of the American Board of Psychiatry and Neurology

2012

Rockefeller University Pilot Award Recipient

2012

Dana Foundation Award Recipient

2011

CTSA Pilot Project Award Recipient

Publications

22

Publications

Selected Publications

Modeling the Blood-Brain Barrier Using Human-Induced Pluripotent Stem Cells. Louise A. Mesentier-Louro, Natalie Suhy, Diede Broekaart, Michael Bula, Ana C. Pereira, Joel W. Blanchard.

Differential expression of tau species and the association with cognitive decline and synaptic loss in Alzheimer's disease. Sivaprakasam R. Saroja, Abhijeet Sharma, Patrick R. Hof, Ana C. Pereira. Alzheimer's and Dementia

Astrocyte-secreted glypican-4 drives APOE4-dependent tau hyperphosphorylation. Sivaprakasam R. Saroja, Kirill Gorbachev, Julia Tcw, Alison M. Goate, Ana C. Pereira. Proceedings of the National Academy of Sciences of the United States of America

View All Publications

Office Locations

Anneberg Building

1468 Madison Avenue Room 20-02A

New York, NY 10029

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Pereira during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

Eisai, Inc.
Sinaptica Therapeutics

Founder/Co-Founder/Partner

Patent applications - MSIP Tech No 180215 and Tech No 200909 licensed to Neurobiopharma LLC

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Pereira during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

Eisai, Inc.
Sinaptica Therapeutics

Founder/Co-Founder/Partner

Patent applications - MSIP Tech No 180215 and Tech No 200909 licensed to Neurobiopharma LLC

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.